Michelle Ols

Company: Obsidian Therapeutics

Job title: Vice President & Head Of Cell Therapy

Seminars:

Panel Discussion: A Commercial TCR-T & TCR Bispecific – What’s Next? 12:00 pm

• Discussing engineering methods to alter T-cell or bispecific properties to increase trafficking to tumor sites and enable prolonged killing • Inhibiting immune suppression pathways to improve cell survival • Considering implications of multi-engineering on cell viability and patient safety to mitigate adverse effectsRead more

day: Day 2